Analysis of Dedifferentiated Liposarcomas Emphasizing the Diagnostic Dilemmas

Abstract

Introduction: Dedifferentiated liposarcoma (DDLPS) is defined as a progression of well-differentiated liposarcoma (WDLPS) to another nonlipogenic sarcoma. Since a variety of heterologous sarcomas can be encountered in dedifferentiation, clinical dilemmas arise. The present study analyzed the role of clinicopathologic and immunohistochemical (IHC) features in the diagnosis of DDLPS and its differentiation from mimics. Materials and Methods: A retrospective and prospective study was conducted wherein all cases of liposarcoma from 2012 to 2017 were reviewed. DDLPS cases were identified among pleomorphic lesions. Clinical and histopathological details for these cases were retrieved from medical records section and department archives. Histomorphology and immunohistochemistry (MDM2, S100, and Ki-67) were analyzed for these cases. Results: Among 37 cases of liposarcomas reviewed, DDLPS was diagnosed in 12 cases (32.4%). Mean age of the patients was 54.3 years with equal gender distribution (M:F =1:1.2). Two patients had recurrent tumors. Most were retroperitoneal (58.3%) with mean duration of symptoms being 8.7 months. Mean tumor dimension was 17.5 cm. High-grade dedifferentiated component was most common (83.3%) with only one case each (8.3%) of low-grade and homologous dedifferentiation. Undifferentiated pleomorphic sarcoma was the frequent nonlipogenic sarcoma. MDM2 overexpression was detected in 100%, focal S100 positivity seen in 66.6%, and mean Ki-67 labeling index was 24. Conclusion: DDLPS exhibits aggressive clinical behavior. Adequate sampling, correlation to clinical details, demonstration of transition from WDLPS to DDLPS aid in narrowing the differentials. Immunostaining with MDM2 helps in definite categorization and S100 highlights lipoblasts, when they are not easily identifiable. MDM2, CDK4, and p16 IHC panel is recommended in all cases and fluorescence in situ hybridization analysis where IHC is noncontributory.

Keywords

Dedifferentiated - liposarcoma - MDM2 - sarcoma

Publication History

Received: 29 May 2019

Accepted: 06 October 2019

Article published online:
23 May 2021

• References

• 1 Brennan MF, Antonescu CR, Moraco N, Singer S. Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Ann Surg 2014; 260: 416-21
• 2 Jo VY, Fletcher CD. WHO classification of soft tissue tumours: An update based on the 2013 (4th) edition. Pathology 2014; 46: 95-104
• 3 de Vreeze RS, de Jong D, Nederlof PM, Ariaens A, Tielen IH, Frenken L. et al. Added value of molecular biological analysis in diagnosis and clinical management of liposarcoma: A 30-year single-institution experience. Ann Surg Oncol 2010; 17: 686-93
• 4 Evans HL. Liposarcoma: A study of 55 cases with a reassessment of its classification. Am J Surg Pathol 1979; 3: 507-23
• 5 Fletcher CD, Bridge JA, Hogendoorn PC, Mertens F. Adipocytic tumours. In: WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. Lyon: International Agency for Research on Cancer; 2013: 33-43
• 6 Amin MB. AJCC Cancer Staging Manual. 8th ed. Chicago: Springer US; 2017: 489-548
• 7 Ikoma N, Torres KE, Somaiah N, Hunt KK, Cormier JN, Tseng W. et al. Accuracy of preoperative percutaneous biopsy for the diagnosis of retroperitoneal liposarcoma subtypes. Ann Surg Oncol 2015; 22: 1068-72
• 8 Knebel C, Lenze U, Pohlig F, Lenze F, Harrasser N, Suren C. et al. Prognostic factors and outcome of liposarcoma patients: A retrospective evaluation over 15 years. BMC Cancer 2017; 17: 410
• 9 Oh YJ, Yi SY, Kim KH, Cho YJ, Beum SH, Lee YH. et al. Prognostic model to predict survival outcome for curatively resected liposarcoma: A multi-institutional experience. J Cancer 2016; 7: 1174-80
• 10 Dei Tos AP. Liposarcomas: Diagnostic pitfalls and new insights. Histopathology 2014; 64: 38-52
• 11 Mastrangelo G, Coindre JM, Ducimetière F, Dei Tos AP, Fadda E, Blay JY. et al. Incidence of soft tissue sarcoma and beyond: A population-based prospective study in 3 European regions. Cancer 2012; 118: 5339-48
• 12 Kalimuthu SN, Tilley C, Forbes G, Ye H, Lehovsky K, Pillay N. et al. Clinical outcome in patients with peripherally-sited atypical lipomatous tumours and dedifferentiated liposarcoma. J Pathol Clin Res 2015; 1: 106-12
• 13 Rekhi B, Navale P, Jambhekar NA. Critical histopathological analysis of 25 dedifferentiated liposarcomas, including uncommon variants, reviewed at a tertiary cancer referral center. Indian J Pathol Microbiol 2012; 55: 294-302
• 14 Singer S, Antonescu CR, Riedel E, Brennan MF. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg 2003; 238: 358-70
• 15 Lu W, Lau J, Xu MD, Zhang Y, Jiang Y, Tong HX. et al. Recurrent abdominal liposarcoma: Analysis of 19 cases and prognostic factors. World J Gastroenterol 2013; 19: 4045-52
• 16 Fletcher CD, Unni KK, Mertens F. Adipocytic tumours. In: Pathology and Genetics of Tumours of Soft Tissue and Bone. 3rd ed. Lyon: International Agency for Research on Cancer; 2002: 35-46
• 17 Mariño-Enríquez A, Fletcher CD, Dal Cin P, Hornick JL. Dedifferentiated liposarcoma with “homologous” lipoblastic (pleomorphic liposarcoma-like) differentiation: Clinicopathologic and molecular analysis of a series suggesting revised diagnostic criteria. Am J Surg Pathol 2010; 34: 1122-31
• 18 Kashima T, Halai D, Ye H, Hing SN, Delaney D, Pollock R. et al. Sensitivity of MDM2 amplification and unexpected multiple faint alphoid 12 (alpha 12 satellite sequences) signals in atypical lipomatous tumor. Mod Pathol 2012; 25: 1384-96
• 19 Touqan N, Diggle CP, Verghese ET, Perry S, Horgan K, Merchant W. et al. An observational study on the expression levels of MDM2 and MDMX proteins, and associated effects on P53 in a series of human liposarcomas. BMC Clin Pathol 2013; 13: 32
• 20 Thway K, Wang J, Swansbury J, Min T, Fisher C. Fluorescence in situ hybridization for MDM2 amplification as a routine ancillary diagnostic tool for suspected well-differentiated and dedifferentiated liposarcomas: Experience at a tertiary center. Sarcoma 2015; 2015: 1-10
• 21 Clay MR, Martinez AP, Weiss SW, Edgar MA. MDM2 and CDK4 immunohistochemistry: Should it be used in problematic differentiated lipomatous tumors?: A new perspective. Am J Surg Pathol 2016; 40: 1647-52
• 22 Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T. et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol 2012; 22: 21-30
• 23 Thway K, Jones RL, Noujaim J, Zaidi S, Miah AB, Fisher C. Dedifferentiated liposarcoma: Updates on morphology, genetics, and therapeutic strategies. Adv Anat Pathol 2016; 23: 30-40
• 24 Fletcher CD. Tumors of soft tissue. In: Diagnostic Histopathology of Tumors. 4th ed. Philadelphia: Elsevier; 2013: 1804-9
• 25 Chen C, Borker R, Ewing J, Tseng WY, Hackshaw MD, Saravanan S. et al. Epidemiology, treatment patterns, and outcomes of metastatic soft tissue sarcoma in a community-based oncology network. Sarcoma 2014; 2014: 1-7
• 26 Patel RB, Li T, Liao Z, Jaldeepbhai JA, Perera HA, Muthukuda SK. et al. Recent translational research into targeted therapy for liposarcoma. Stem Cell Investig 2017; 4: 21